McCullough Andrew
New York University School of Medicine, 150 East 32nd Street, Second Floor, New York, NY 10016, USA.
Curr Urol Rep. 2004 Dec;5(6):451-9. doi: 10.1007/s11934-004-0070-2.
The purpose of this review is to examine the biologic, pharmacologic, and clinical differences between the three currently approved phosphodiesterase-5 inhibitors to help the clinician make an educated choice about which medication may be best for any individual patient.
本综述的目的是研究三种目前已获批的磷酸二酯酶-5抑制剂在生物学、药理学和临床方面的差异,以帮助临床医生针对具体患者做出关于哪种药物可能最为合适的明智选择。